Clinical trial
Immunogenicity Study of the Influenza Vaccine in Adults
NCT00258934 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00258934 |
|---|---|
| Title | Immunogenicity Study of the Influenza Vaccine in Adults |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Orthomyxoviridae Infections, Influenza |
| Intervention type | Biological |
| Interventions | Inactivated, split-virion influenza vaccine, split-virion, influenza virus |
| Enrollment | 978 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Nov 28, 2005 |
| Last update posted | Jan 14, 2014 |
| Countries | Belgium, Germany, Switzerland |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: